Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2019 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
MIRM on Nasdaq
Shares outstanding
51,400,915
Price per share
$92.32
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
61,021,397
Total reported value
$4,819,939,526
% of total 13F portfolios
0.01%
Share change
+3,551,635
Value change
+$287,587,807
Number of holders
276
Price from insider filings
$92.32
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 12% +11% $479,098,679 +$48,995,048 6,065,308 +11% JANUS HENDERSON GROUP PLC 31 Dec 2025
Frazier Life Sciences IX, L.P. 6.8% -8.6% $324,522,832 +$29,477,804 4,108,404 +10% Patrick J. Heron 23 Jan 2026
EVENTIDE ASSET MANAGEMENT, LLC 4.1% -27% $165,372,042 -$40,549,990 2,093,582 -20% Eventide Asset Management, LLC 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P 3% $109,619,710 1,495,290 BVF PARTNERS L P/IL 30 Sep 2025

As of 31 Dec 2025, 276 institutional investors reported holding 61,021,397 shares of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM). This represents 119% of the company’s total 51,400,915 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Frazier Life Sciences Management, L.P. 13% 6,795,121 0% 14% $536,746,608
JANUS HENDERSON GROUP PLC 12% 6,065,308 +21% 0.21% $479,050,121
BlackRock, Inc. 7.1% 3,645,286 +1.2% 0% $287,941,139
VANGUARD GROUP INC 5.1% 2,596,089 +2% 0% $205,065,069
STATE STREET CORP 4.2% 2,143,992 +59% 0.01% $169,353,928
EVENTIDE ASSET MANAGEMENT, LLC 4.1% 2,093,582 -17% 2.6% $165,370,112
BVF INC/IL 2.9% 1,495,290 0% 4% $118,112,957
PRICE T ROWE ASSOCIATES INC /MD/ 2.8% 1,420,375 +11% 0.01% $112,196,000
NOVO HOLDINGS A/S 2.5% 1,264,028 0% 7.8% $99,845,572
WELLINGTON MANAGEMENT GROUP LLP 2.4% 1,237,830 +57% 0.02% $97,776,191
TANG CAPITAL MANAGEMENT LLC 2.4% 1,236,027 0% 4.8% $97,633,773
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,062,926 +5.2% 0.01% $83,975,140
D. E. Shaw & Co., Inc. 1.8% 948,161 +2.7% 0.06% $74,895,237
Clearbridge Investments, LLC 1.7% 865,967 -14% 0.05% $68,402,733
CITADEL ADVISORS LLC 1.6% 840,220 -19% 0.05% $66,368,978
Polar Capital Holdings Plc 1.5% 793,642 -3.3% 0.29% $62,689,782
Rock Springs Capital Management LP 1.5% 762,294 +0.15% 3.1% $60,213,603
GOLDMAN SACHS GROUP INC 1.4% 724,317 +61% 0.01% $57,213,800
BANK OF AMERICA CORP /DE/ 1.4% 713,452 +83% 0% $56,355,574
BNP PARIBAS FINANCIAL MARKETS 1.3% 655,778 0% 0.03% $51,799,904
FRANKLIN RESOURCES INC 1.3% 650,715 +8.2% 0.01% $51,399,978
FMR LLC 1.3% 646,466 +0.98% 0% $51,064,384
LORD, ABBETT & CO. LLC 1.1% 579,983 -12% 0.14% $45,813,000
Pictet Asset Management Holding SA 1.1% 577,274 +6.7% 0.04% $45,598,873
Soleus Capital Management, L.P. 1.1% 573,614 +286% 1.9% $45,309,770

Institutional Holders of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 61,021,397 $4,819,939,526 +$287,587,807 $78.99 276
2025 Q3 57,251,922 $4,197,137,135 +$132,883,151 $73.31 268
2025 Q2 55,393,029 $2,819,019,204 +$70,434,976 $50.89 211
2025 Q1 54,142,705 $2,443,759,313 +$49,081,267 $45.05 213
2024 Q4 52,986,109 $2,190,964,431 -$26,045,809 $41.35 204
2024 Q3 53,301,609 $2,079,251,226 -$2,890,149 $39.00 176
2024 Q2 53,362,791 $1,824,471,702 +$17,964,526 $34.19 157
2024 Q1 53,243,448 $1,337,601,222 +$70,337,692 $25.12 167
2023 Q4 50,259,606 $1,483,847,413 +$1,676,068 $29.52 184
2023 Q3 48,930,333 $1,545,592,030 +$398,674,334 $31.60 156
2023 Q2 36,937,639 $955,518,729 +$63,103,719 $25.87 143
2023 Q1 34,669,406 $832,753,531 +$33,992,984 $24.02 114
2022 Q4 33,331,988 $650,146,380 -$12,725,497 $19.50 101
2022 Q3 33,748,714 $709,089,633 +$93,197,315 $21.01 107
2022 Q2 29,289,263 $568,434,366 +$47,575,699 $19.46 104
2022 Q1 26,813,353 $590,437,915 -$6,195,298 $22.02 99
2021 Q4 22,891,220 $365,087,000 +$18,990,411 $15.95 81
2021 Q3 21,414,209 $426,514,254 +$2,080,056 $19.92 69
2021 Q2 21,482,092 $371,413,185 +$642,669 $17.29 66
2021 Q1 21,451,984 $425,174,000 -$8,433,468 $19.82 60
2020 Q4 22,010,623 $384,380,000 +$52,268,047 $17.46 71
2020 Q3 18,743,135 $361,180,000 -$1,290,295 $19.27 50
2020 Q2 18,808,446 $366,015,000 +$8,936,163 $19.46 57
2020 Q1 18,603,225 $260,445,000 +$32,083,278 $14.00 43
2019 Q4 16,248,910 $398,421,000 +$12,819,124 $24.52 39
2019 Q3 16,487,274 $165,856,000 +$165,755,000 $10.06 38